Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Nov;247(2):596-602.

Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium

Affiliations
  • PMID: 3183955

Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium

F J Ehlert. J Pharmacol Exp Ther. 1988 Nov.

Abstract

The ability of gallamine to modify muscarinic receptor binding properties and to antagonize muscarinic receptor-mediated inhibition of adenylate cyclase activity was investigated in the rat myocardium. Gallamine caused parallel shifts to the right in the dose-response curves for inhibition of adenylate cyclase activity by the highly efficacious muscarinic agonist oxotremorine-M and the partial agonist Bm 5 [N-methyl-N-(1-methyl-4-pyrrolidino)-2-butynyl acetamide]. The nature of this effect was inconsistent with competitive inhibition, but could be explained by allosteric antagonism. Similar dissociation constants of 0.52 and 0.83 microM were estimated for gallamine on the basis of its ability to antagonize responses to oxotremorine-M and Bm 5, respectively. The maximum shift in the dose-response curve of Bm 5 caused by gallamine was 90-fold, whereas that of oxotremorine-M was only 49-fold. When measured by inhibition of the binding of the specific muscarinic antagonist [3H]N-methylscopolamine, the dissociation constant of gallamine was estimated to be 1.1 microM. The present results illustrate good agreement between the ability of gallamine to modify muscarinic receptor binding properties and to antagonize muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat heart.

PubMed Disclaimer

Publication types